Campral
In brief
- In our pharmacy, you can buy campral without a prescription or receipt, with delivery across Australia in 9–21 days and discreet, anonymous packaging.
- Campral (acamprosate) is used as an adjunctive treatment to help maintain abstinence in alcohol‑dependent people who have already stopped drinking, usually alongside counselling; it is thought to modulate glutamatergic and GABAergic neurotransmission to restore neurochemical balance after chronic alcohol use.
- The usual adult dose is 666 mg three times a day (two 333 mg tablets per dose, total about 1998 mg per day); dose adjustments are required for renal impairment and as advised by a clinician.
- Campral is given orally as enteric‑coated, delayed‑release tablets (each tablet 333 mg acamprosate calcium, white round tablet debossed “333”).
- Clinical benefit is not immediate — many people notice effects within 1–2 weeks, although it can take up to 4 weeks to see a clear improvement in cravings and maintenance of abstinence.
- The therapeutic effect is maintained while the medicine is taken; steady state is reached after several days and the drug is taken three times daily to sustain effect (plasma elimination half‑life is in the order of a day or two).
- Do not drink alcohol while taking campral — it is intended to support abstinence, and drinking undermines its purpose and may increase risks.
- The most common side effect is diarrhoea; other frequent adverse effects include nausea, abdominal pain and rash — seek advice if side effects are severe or persistent.
- Would you like to try “campral” without a prescription?
Basic Campral Information
- INN (International Nonproprietary Name): Acamprosate (often specified as acamprosate calcium).
- Brand Names Available In Australia: Campral.
- ATC Code: N07BB03.
- Forms & Dosages: Enteric‑coated, delayed‑release oral tablets; each tablet contains 333 mg acamprosate calcium (equivalent to 300 mg acamprosate); white, round, biconvex tablet debossed “333”.
- Manufacturers In Australia: Not specified.
- Registration Status In Australia: Prescription only; check the TGA ARTG and PBS for current registration and subsidy details.
- OTC / Rx Classification: Prescription only.
Critical Warnings, Restrictions & Patient Protection (Australia)
Is Campral the first step when someone wants to stop drinking?
Campral (acamprosate calcium) is prescribed as an adjunctive therapy to maintain abstinence after a person has already stopped drinking.
This medicine is intended to be used alongside counselling or psychosocial support, not as a standalone cure.
Use this treatment only under medical supervision and with a clear relapse‑prevention plan in place.
Elderly patients require extra caution because renal function often declines with age and acamprosate is primarily cleared by the kidneys.
Pregnant or breastfeeding people have limited data available and treatment should be avoided unless clinically necessary and after specialist advice.
Patients with severe renal impairment may need dose adjustment or must not use acamprosate depending on creatinine clearance.
Severe hepatic disease warrants caution even though the drug is not extensively metabolised in the liver.
Polypharmacy raises risks; perform a full medication reconciliation including prescriptions, over‑the‑counter medicines and supplements.
People with unstable psychiatric illness or active suicidal ideation are high risk and require close mental health input before and during therapy.
Pharmacists should verify kidney function before initiation and arrange regular renal monitoring during treatment.
A written action plan for recognising relapse signs and what to do must be provided to the patient.
Ensure a counselling or psychosocial referral is established before or at the start of medication.
Use the dispensing checklist when supplying Campral: renal function documented, counselling arranged, pregnancy status checked, and pharmacy counselling provided.
Advise patients that workplace safety, driving and licensing responsibilities remain governed by Australian law and employer policies.
High‑Risk Activities, Driving & Workplace Safety
What does Campral mean for people who drive or work in safety‑sensitive roles?
Acamprosate itself is not considered sedating in the available product literature.
Residual effects from alcohol withdrawal, concurrent sedatives or ongoing intoxication are the primary safety risks for driving and operation of heavy machinery.
People employed in safety‑sensitive roles should follow employer and insurer rules about disclosure and fitness for work.
Fitness to drive in Australia is determined by impairment rather than simply by whether a person is taking a specific medicine.
If dizziness, sedation, confusion or ongoing withdrawal symptoms are present, do not drive and seek medical advice promptly.
Micro‑FAQ: “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking Campral?
A: Campral alone is not typically associated with sedation, but if withdrawal symptoms, other sedating medicines or unsteadiness are present you must not drive.
- Examples Of Safety‑Sensitive Roles: heavy machinery operator, commercial driver, pilot, emergency services worker, rail or maritime operator, forklift operator.
- Symptoms That Preclude Driving: dizziness, severe fatigue, confusion, ongoing intoxication, poor concentration, loss of balance.
Usage Basics: INN, Brand Names & Legal Classification
Which names will patients and prescribers see on labels?
The International Nonproprietary Name (INN) is acamprosate, often listed as acamprosate calcium in product documents.
The primary global brand name is Campral and some labels use Campral EC for the enteric‑coated formulation.
Acamprosate is classified under the WHO ATC code N07BB03 for drugs used in alcohol dependence.
Campral is supplied as enteric‑coated, delayed‑release oral tablets to improve gastric tolerance and absorption.
Each tablet contains 333 mg acamprosate calcium, equivalent to 300 mg acamprosate, and is debossed “333”.
Regulatory status in Australia is prescription only; pharmacists should confirm current subsidy rules at PBS.gov.au before advising on cost.
- INN: Acamprosate.
- Brand: Campral.
- ATC: N07BB03.
- Dosage Strength: 333 mg acamprosate calcium per tablet (equivalent to 300 mg acamprosate).
Dosing Guide And Renal/Hepatic Adjustments
How is Campral usually taken and what checks are needed beforehand?
Common maintenance dosing described in product literature is 666 mg three times daily, often given as two 333 mg tablets per dose.
Always follow the prescriber’s instruction and the local product information for the exact regimen.
Because acamprosate is mainly eliminated via the kidneys, check baseline serum creatinine or eGFR before initiation.
Dose adjustments or avoidance are required in moderate to severe renal impairment and renal function should be repeated periodically.
Acamprosate is not extensively hepatically metabolised, but exercise caution in severe hepatic disease.
Use this renal checklist before dispensing: baseline renal function documented, repeat schedule agreed, and action thresholds for dose change or discontinuation recorded.
Micro‑FAQ: “What If I Miss A Dose?”
Q: Missed dose?
A: Take the missed dose as soon as remembered unless it is near the next scheduled dose, and do not double up.
- Dosing Reminders: use a daily pill box, blister packs, or SMS/phone reminders to support adherence.
- Adherence Strategies: set fixed dosing times, involve a support person, arrange automatic pharmacy refill reminders.
Interaction Chart: Alcohol, Food & Common Drug Conflicts
Will Campral mix badly with food, alcohol or other medicines?
Campral is intended for people who have already stopped drinking, and alcohol consumption undermines the treatment goals.
Resuming alcohol while on acamprosate increases the risk of relapse and reduces the expected benefit of therapy.
There are no major food interactions noted and it can be taken with or without food.
Acamprosate has low systemic metabolism and relatively few pharmacokinetic interactions, but clinical interactions may occur with CNS depressants and certain psychiatric medicines.
| Substance | Interaction Type | Clinical Action |
|---|---|---|
| Alcohol | Clinical counter‑productive effect | Advise abstinence; discuss relapse plan and support services. |
| Benzodiazepines | Potential additive CNS effects | Monitor sedation and coordination; consider dose review. |
| Opioids | Potential additive respiratory/CNS depression | Warn about sedation; coordinate with prescriber for monitoring. |
| Sedating Antidepressants | Possible additive CNS effects | Review mental health status and monitor side effects. |
| Anticonvulsants | Clinical interaction risk due to CNS effects | Monitor for increased adverse effects; liaise with specialist if needed. |
- Substances Of Concern: alcohol, benzodiazepines, opioids, sedating antidepressants, anticonvulsants.
- Recommended Monitoring: assess sedation, respiratory status, mood and adherence frequently, and provide clear counselling on avoiding alcohol.
User Reports, Trends & Patient Experience
What do Australian patients commonly say about Campral?
Consumer feedback often describes a reduction in craving for some users while others notice little change.
Gastrointestinal side effects such as diarrhoea or stomach upset are commonly reported, especially early in treatment.
Individual responses vary, and realistic expectations should be set during counselling.
Useful sources for clinicians include ProductReview-type feedback, pharmacy counselling notes, peer support group observations and local drug and alcohol services.
Clinicians are encouraged to document patient‑reported outcomes and any adverse events in medical records.
- Common Patient Comments: decreased craving, early GI upset, variable benefit timeline.
- Actionable Clinician Responses: normalise transient GI effects, suggest symptom management, reinforce psychosocial supports.
Follow‑up should capture symptom score, adherence, adverse events and engagement with support services at scheduled reviews.
Access & Purchase Options In Australia
Where can patients obtain Campral in Australia?
Supply is generally by prescription and is available from community pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart, independent pharmacies and hospital outpatient pharmacies.
Approved online pharmacies with e‑prescriptions may supply medication subject to verification of the e‑script and patient identity.
Telehealth and electronic prescribing are widely used, and pharmacists should verify e‑scripts before supply.
Rural towns may have limited stock, and pharmacist‑led emergency supplies or inter‑pharmacy transfers can help bridge access gaps.
Check the PBS listing and subsidy status before advising patients on cost and likely out‑of‑pocket expense.
Compare pharmacy convenience, price, counselling services and delivery options when advising patients on where to fill a prescription.
| Source | Prescription Type | Likely Turnaround | Counselling Availability |
|---|---|---|---|
| Community Pharmacy (Chain) | Prescription | Same day to 48 hours | High |
| Independent Pharmacy | Prescription | Same day to 48 hours | High |
| Hospital Outpatient Pharmacy | Prescription | 1–7 days | High (specialist support) |
| Approved Online Pharmacy | e‑Prescription | 2–14 days (delivery) | Variable (phone/online counselling) |
- Steps To Obtain Medication: see a prescriber, confirm subsidy if applicable, present prescription or e‑script, collect from pharmacy or arrange delivery.
- Note: In this online pharmacy, campral is available without a prescription with discreet delivery to Australia in 9‑21 days.
Mechanism Of Action & Pharmacology
How does acamprosate support abstinence in plain language?
Acamprosate is believed to modulate glutamatergic and GABAergic neurotransmission to reduce post‑withdrawal hyperexcitability and craving.
The enteric‑coated, delayed‑release tablet improves gastric tolerance and intestinal absorption.
Renal elimination is significant, making kidney function important for dosing and clearance.
Clinical effect is described as a supporting medication to help maintain abstinence when combined with psychosocial therapy.
- Mechanism: modulates glutamate and GABA pathways to reduce withdrawal hyperexcitability.
- Formulation: enteric‑coated, delayed‑release oral tablet.
- Elimination: predominantly renal.
- Clinical Effect: supports maintenance of abstinence when paired with counselling.
- Key Takeaways For Patients: it helps reduce cravings over weeks, is not a quick fix, and must be used with counselling for best effect.
Indications, Approved Use & Off‑Label Considerations
Who is Campral approved for and when should it be considered?
The approved indication is as an adjunctive therapy to maintain abstinence in alcohol‑dependent patients who have already stopped drinking, typically combined with counselling or psychosocial support.
Confirm the exact TGA wording on the ARTG entry when advising about formal indications and any provisos.
Prescription‑only status applies; follow local clinical guidance before initiating therapy.
Off‑label use may be considered in specialist or research settings for particular subgroups, but must be justified and documented.
Initiation is recommended only after detox and a medical assessment and should be embedded within a relapse prevention plan.
- Checklist For Prescribers: detox complete, renal assessment done, counselling referral arranged, informed consent documented.
Key Clinical Evidence & Outcomes Summary
What does the evidence say about effectiveness and safety?
Clinical trials and meta‑analyses support a modest but meaningful effect of acamprosate in increasing days abstinent and reducing relapse risk when used after cessation with psychosocial support.
Effect sizes vary across studies and patient populations, so individual outcomes may differ.
Australian treatment services commonly include acamprosate as an option within multimodal care pathways.
Gastrointestinal adverse events are the most commonly reported side effects and are usually transient.
Serious adverse events are uncommon, but monitoring for mood changes and suicidal ideation is recommended.
- Benefit: increased days abstinent and reduced relapse risk when combined with counselling.
- Common Adverse Events: diarrhoea, abdominal discomfort.
- Monitoring Priorities: renal function, mood and suicidal ideation screening, adherence.
Clinicians should review up‑to‑date Australian clinical guidelines, systematic reviews and the TGA product information before prescribing.
Alternatives Matrix: Naltrexone, Disulfiram & Psychosocial Options
What alternatives should be considered when Campral is not suitable?
Naltrexone, disulfiram and structured psychosocial interventions are commonly considered alternatives in Australia.
Naltrexone is an opioid antagonist and is contraindicated in people currently using opioids.
Disulfiram produces an aversive reaction to alcohol and requires high adherence and detailed counselling about risks.
Psychosocial interventions such as CBT, mutual support and counselling are essential components of treatment regardless of medication choice.
| Medication | Mechanism | Key Contraindications | Typical Monitoring | Pros/Cons |
|---|---|---|---|---|
| Naltrexone | Opioid receptor antagonist | Current opioid use or opioid dependence | Assess liver enzymes and discuss opioid avoidance | Pros: reduces rewarding effects of alcohol. Cons: hepatic monitoring, opioid contraindication. |
| Disulfiram | Aversion therapy via aldehyde dehydrogenase inhibition | Cardiovascular disease, severe hepatic disease | Supervised dosing recommended, assess adherence | Pros: strong deterrent. Cons: severe reaction with alcohol; adherence issues. |
| Psychosocial Interventions | Behavioural and support therapies | None specific | Regular therapy engagement and outcome review | Pros: foundational treatment. Cons: access and wait times can limit use. |
- Checklist For Choosing Therapy: consider patient preference, comorbidities, pregnancy, opioid use, hepatic and renal function, and psychosocial support availability.
- Clinical Tip: combine pharmacotherapy with structured psychosocial interventions and document shared decision‑making.
Common Pharmacy & Patient FAQs
Which questions come up most during Australian pharmacy consultations?
How soon will it work?
Onset: several weeks may be required for reduction in craving.
What side effects should I expect?
Side effects: commonly diarrhoea and gastrointestinal upset early in treatment.
Can I stop if I feel better?
Stopping: consult the prescriber before stopping to agree a safe plan.
Will it interact with my other meds?
Interactions: relatively few pharmacokinetic interactions but watch for additive CNS depressant effects and renal impairment.
Is it covered on the PBS?
PBS: check PBS.gov.au for current subsidy status before advising about cost.
- Communication Tips For Pharmacists: use plain language, confirm renal function, arrange follow‑up and provide written information with referral contacts for AOD services.
Price, Subsidy & Access Comparison
How much will Campral cost and where is it easiest to get?
Campral is prescription‑only and subsidy status on the PBS can change; verify current listings and patient eligibility before advising on cost.
Community pharmacies, hospital pharmacies, online pharmacies and public AOD services are practical access points.
Consider pharmacy delivery if mobility or distance limits patient access, especially for rural patients.
| Source | PBS Subsidy (Verify) | Typical Process | Rural Availability Notes |
|---|---|---|---|
| Chain Community Pharmacy | Verify | Prescription presented, same day to 48 hours | Usually stocked in regional centres; may need transfer for remote areas |
| Hospital Pharmacy | Verify | Prescription or discharge supply, 1–7 days | Accessible via outpatient services; supply may be limited in remote hospitals |
| Online Pharmacy | Verify | e‑Prescription verification, delivery 9–21 days | Useful for remote patients but check delivery times and counselling options |
- Checklist For Patients Before Filling: have the prescription, bring concession card if eligible, request pharmacist counselling, consider delivery if required.
Storage, Dispensing & Handling
How should Campral be stored at home?
Store at room temperature in a cool dry place away from direct sunlight and moisture.
Avoid bathroom storage where humidity is high, especially in Australian climates with hot, humid summers.
Keep medication out of reach of children.
Pharmacies should store as per product information and ensure blister packs remain intact until dispensing.
Enteric‑coated tablets must not be crushed or split as this affects delayed release.
No cold chain is required.
Expired or unused tablets should be returned to a pharmacy for safe disposal rather than thrown in household rubbish.
- Patient Storage Tips: keep in original packaging, avoid heat and humidity, use a pill organiser that protects from moisture if needed.
- Pharmacy Dispensing Checklist: verify integrity of blister, label with counselling points, document counselling provided.
- Definition: Enteric‑Coated — a protective coating that prevents tablet dissolution in the stomach and allows release in the intestine; do not crush.
Guidelines For Proper Use, Counselling & Follow‑Up
What follow‑up and counselling should accompany Campral therapy?
Adopt a collaborative, non‑judgemental counselling style and set realistic abstinence goals with the patient.
Explain the role of medication as an adjunct to psychosocial therapy, and discuss expected timelines and side effects.
Baseline renal function is essential before starting treatment.
Schedule follow‑ups 2–4 weeks after initiation for early review and then at regular intervals to monitor adherence and adverse events.
Include mental health screening at follow‑ups and specifically ask about suicidal thoughts.
Use this practical patient checklist: complete detox, baseline renal test, start medication with counselling arranged, follow‑up appointment booked, and have an emergency contact and relapse plan in place.
Refer patients to local alcohol and other drug services, psychologists, peer support groups and arrange GP shared‑care where appropriate.
Document informed consent, rationale for the chosen therapy, discussion of alternatives and scheduled review dates in the medical record.
Recording these details supports clinical governance and medicolegal best practice.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 14–21 days |
| Sunshine Coast | Queensland | 14–21 days |
| Geelong | Victoria | 14–21 days |
| Cairns | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |